论文部分内容阅读
目的观察重组人干扰素α-2b与炎琥宁注射液分别联合利巴韦林对小儿手足口病的预后影响差异。方法将300例手足口病患儿随机分为A、B、C组各100例。A组给予重组人干扰素α-2b联合利巴韦林治疗,B组给予炎琥宁注射液联合利巴韦林治疗,而C组仅给予利巴韦林治疗,对比3组临床疗效和并发症差异。结果 A组、B组痊愈率均高于C组,并发症发生率均低于C组,差异均有统计学意义(P<0.05)。但A组、B组痊愈率和并发症发生率差异无统计学意义(P>0.05)。结论重组人干扰素α-2b与炎琥宁注射液分别联合利巴韦林治疗小儿手足口病均具有良好的预后。
Objective To observe the difference of the prognosis of HFMD in children treated with recombinant interferon alfa-2b and Yanhuning injection combined with ribavirin respectively. Methods 300 cases of hand, foot and mouth disease were randomly divided into A, B, C group of 100 cases. Group A received recombinant interferon alfa-2b combined with ribavirin, Group B received Yanhuoning injection combined with ribavirin, while Group C received only ribavirin, compared with the clinical efficacy and concurrent Disorder Results The cure rates of group A and group B were higher than those of group C, and the complication rates were lower than those of group C (P <0.05). However, there was no significant difference in the cure rate and complication between group A and group B (P> 0.05). Conclusion Recombinant human interferon α-2b and Yanhuning injection combined with ribavirin respectively have a good prognosis in the treatment of hand-foot-mouth disease in children.